|
Serum Testosterone and Systolic Blood Pressure at 15 Weeks |
||||
| Strain |
Treatment |
Serum Testosterone (ng/ml) |
Systolic Blood Pressure (SBP, mmHg) |
Relative Kidney Weight (mg/100 g BW) |
|
|
||||
| SHR/y |
control |
5.6 +/-1.4 |
+++,&&&155.8+/-3.1 |
764+/-36.0 |
| SHR/y |
cast |
0.05+/-0.02 |
136.8+/-1.6 |
###616+/-23.0 |
| SHR/y |
cast +Ti |
+++14.84+/-0.51 |
142.2+/-2.4 |
$$916+/-19.0 |
| WKY |
control |
3.28+/-0.16 |
137.6+/-2.3 |
658+/-17.0 |
| WKY |
cast |
0.19+/-0.07 |
%126.0+/-4.6 |
636+/-24.0 |
| WKY |
cast +Ti |
+++12.44+/-2.00 |
144.4+/-5.7 |
783+/-77.0 |
|
Serum testosterone (T) levels, systolic blood pressure and relative kidney weight at 15 weeks of age for SHR/y and WKY gonadally intact control (control), castrate (cast) and castrate with T implant (cast+Ti) males, expressed as means +/- SEM. The two-way ANOVA for serum T was significant for T treatment) F = 226.0, p < 0.001). Both T implant groups had elevated T compared to controls (+++ = p < .001). The two-way ANOVA for SBP was significant for T treatment (F = 8.1, p = 0.005), strain (F = 6.2, p = 0.001), and T treatment x strain (F = 4.9, p = 0.003). The two-way ANOVA for T treatment on relative combined kidney weight was significant (F = 99.1, p < 0.001). The SHR/y control group SBP was greater than the SHR/y cast+Ti (+++ = p < 0.01) and SHR/y cast group SBP (&&&= p < 0.001). The WKY cast group SBP was less than the WKY cast+Ti and control groups (% = p < 0.05). Relative combined kidney weight for SHR/y cast was significantly less than SHR/y control and SHR/y cast +Ti groups (### = p < 0.001). relative combined kidney weight for the SHR/y cast +Ti group was significantly greater than the SHR/y cast and control groups ($$ = p < 0.01). | ||||
Toot et al. BMC Physiology 2008 8:5 doi:10.1186/1472-6793-8-5 |
||||